CTOs on the Move

Tranquis Therapeutics

www.tranquis.com

 
Tranquis Therapeutics is discovering and developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place on patients, families and societies worldwide.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.tranquis.com
  • 951 Mariners Island Blvd Suite 300
    San Mateo, AB USA 94404
  • Phone: 650.684.8950

Executives

Name Title Contact Details

Funding

Tranquis Therapeutics raised $30M on 07/09/2020

Similar Companies

Dzeel Clinical

Dzeel Clinical is a Garner, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioMarker Strategies

BioMarker Strategies is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mendel Biotechnology

Mendel Biotechnology is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

New Horizon Agency Group

New Horizon Agency Group is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allucent

Allucent is a global biopharmaceutical services company founded in 2022 through the merger of several specialized providers. The company focuses on supporting small and mid-sized biotech firms in developing innovative treatments for patients with unmet medical needs. With over 30 years of combined experience, Allucent offers a range of services including regulatory consulting, clinical operations management, biometrics, and clinical pharmacology, particularly emphasizing oncology. Headquartered in Cary, North Carolina, Allucent has a strong global presence with offices in North America, Europe, Central/Eastern Europe, and Asia/Middle East. The company has conducted more than 825 clinical trials across over 70 countries, showcasing its extensive operational expertise. Allucent is dedicated to helping clients navigate the complexities of drug development and regulatory approval, ultimately accelerating the delivery of breakthrough therapies to patients.